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Abstract
Background: Recent refinements of lung MRI techniques have reduced the examination time and improved
diagnostic sensitivity and specificity. We conducted a study to assess the feasibility of MRI for the detection of
primary lung cancer in asymptomatic individuals.
Methods: A retrospective chart review was performed on images of lung parenchyma, which were extracted from
whole-body MRI examinations between October 2000 and December 2007. 11,766 consecutive healthy individuals
(mean age, 50.4 years; 56.8% male) were scanned using one of two 1.5-T scanners (Sonata and Sonata Maestro,
Siemens Medical Solutions, Erlangen, Germany). The standard protocol included a quick whole-lung survey with T2-
weighted 2-dimensional half Fourier acquisition single shot turbo spin echo (HASTE) and 3-dimensional volumetric
interpolated breath-hold examination (VIBE). Total examination time was less than 10 minutes, and scanning time
was only 5 minutes. Prompt referrals and follow-ups were arranged in cases of suspicious lung nodules.
Results: A total of 559 individuals (4.8%) had suspicious lung nodules. A total of 49 primary lung cancers were
diagnosed in 46 individuals: 41 prevalence cancers and 8 incidence cancers. The overall detection rate of primary
lung cancers was 0.4%. For smokers aged 51 to 70 years, the detection rate was 1.4%. TNM stage I disease
accounted for 37 (75.5%). The mean size of detected lung cancers was 1.98 cm (median, 1.5 cm; range, 0.5-8.2 cm).
The most histological types were adenocarcinoma in 38 (77.6%).
Conclusion: Rapid zero-dose MRI can be used for lung cancer detection in a healthy population.
Background
Lung cancer is the leading cause of cancer death world-
wide [1-3]. The overall 5-year survival rate is approxi-
mately 15% in the United States and less than 10% in
Europe [4-6]. Because most lung cancers generate no
symptoms at early stages, they are usually diagnosed at an
advanced stage and have a poor prognosis. However,
many lung cancer deaths could be avoided if tumors were
detected at an early stage when they were still resectable.
For stage Ia non-small cell lung cancer, the 5-year survival
rate is higher than 80%. Prognosis and treatment
outcomes have been found to be related to the disease
stage at the time of diagnosis [7-9]. Various modalities
have been investigated for detecting early lung cancer and
consequently reducing lung cancer mortality. In the 1970s,
several randomized controlled trials of chest radiography,
alone or combined with sputum cytology, were performed.
However, because of the poor sensitivity of these methods,
the reported data indicated no evidence of benefit in terms
of reduction in lung cancer mortality [10-12]. In the 1990s,
many observational clinical trials were begun of low-dose
spiral computed tomography (LDCT). Those studies
showed that although LDCT can detect more early lung
cancers than chest radiography, it does not result in a
decrease in lung cancer deaths [13-19].
Until recently, magnetic resonance imaging (MRI) was
regarded as an inappropriate tool for lung cancer
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screening because of its insufficient anatomic detail,
along with being time-consuming and expensive. The
advanced MRI techniques for lungs have reduced the
examination time to less than 10 minute (< 8 breath-
holds) and improved diagnostic sensitivity and specifi-
city. We conducted a study to assess the feasibility of
performing rapid MRI for lung cancer detection. We
report our techniques and findings herein.
Methods
Population
In October 2000, Taipei Veterans General Hospital in
Taiwan launched whole-body MRI examinations in rou-
tine clinical practice [20]. All examinations were paid
for by the examinees, who were referred from clinician
or self-registered. So far, more than 20,000 examinations
have been carried out for 17,000 people. We performed
a retrospective chart review for all whole-body MRI
examinations between October 2000 and December
2007. Institutional Review Board of Taipei Veterans
General Hospital in Taiwan approved this retrospective
chart review and waived the requirement for informed
consent because all images and follow-up data were
obtained as part of routine clinical care (VGHIRB No:
201006010IC).
For this study, analysis was focused on images of lung
parenchyma. We did not take into account imaging
findings of the mediastinum, chest wall, diaphragm, or
metastatic lung lesions diagnosed simultaneously with
primary cancer. Examinees with a prior history of cancer
were excluded from the study. Examinees with normal
lung imaging but diagnosed with other cancers by
whole-body MRI were also excluded. Demographic
details of examinees as well as smoking habits and prior
medical history were analyzed.
MRI
All images were acquired using either one of two 1.5-T
scanners (Sonata and Sonata Maestro, Siemens Medical
Solutions, Erlangen, Germany). The standard protocols
followed for lung examinations consisted of two compo-
nents. The first involves a quick whole-lung survey with
T2-weighted 2-dimensional half Fourier acquisition single
shot turbo spin echo (2D HASTE), using the turbo spin
echo technique with double inversion recovery black
blood preparation electrocardiogram triggered in axial,
coronal, and sagittal orientations with repetition time (TR)
of one RR interval, echo time (TE) of 41 ms, flip angle of
160°, slice thickness of 6 mm, and matrix of 172 × 256.
The examination time was less than 3 minutes (Figure 1).
The second protocol component was performed with
3-dimensional axial image acquisition using the volu-
metric interpolated breath-hold examination (3D VIBE)
technique with fat suppression, TR/TE of 4.9 ms/2.1 ms,
flip angle of 12°, field of view (FOV) of 320-360 mm,
matrix of 176 × 256, and slice thickness of 3 mm with
64 slices per breath hold. The duration time for this
sequence was less than 3 minutes (Figure 2).
All examinees could choose their own MRI examina-
tions, either noncontrasted whole-body MRI or with
additional contrasted MRI examinations, such as con-
trast magnetic resonance angiography (MRA) or breast
MRI. For examinees who had additional contrasted
MRI, HASTE was applied before contrast agent injec-
tion, and VIBE was applied after contrast agent injection
using 0.5 mmol/kg of gadodiamide (Omniscan) at an
injection rate of 3 mL/sec.
Image Analysis
All images were viewed by 1 of 5 radiologists (HCC,
JSK, YCC, PWL, WCL), who had 4 to 19 years of
experience (average, 9.6 years) after board certification.
We classified and defined all lesions as (1) normal or
extrapulmonary abnormality: negative result in lungs or
lesions in the extrapulmonary area, for instance, in the
neck or abdomen, (2) lung abnormality of little clinical
significance: pulmonary lesions rather than nodules, for
instance, pleural thickening or fibrosis, (3) probable
benignancy: lung nodules measuring ≤ 0.5 cm with well-
defined border and visible only by VIBE and not by
HASTE, (4) indeterminate nodules: lung nodules mea-
suring ≤ 0.5 cm with mild irregular border and visible
only by VIBE and not by HASTE, (5) possible malig-
nancy: lung nodules measuring > 0.5 cm and <1 cm and
visible only by VIBE and not by HASTE, (6) probable
malignancy: lung nodules visible by both VIBE and
HASTE; or lung nodules measuring ≥ 1 cm; or newly
developed lung nodules at the second or more MRI
examinations. The latter three were considered to be
suspicious lung nodules [16,20].
For examinees with possible malignancies or indeter-
minate small lung nodules, serial follow-ups were
arranged either by MRI or by standard-dose computed
tomography (CT) every 3 to 6 months for a minimum
of 24 months. Nodules remaining the same size or
regressing during follow-up for at least 2 years were
considered to be benign [21,22]. When growth was
found, referrals to thoracic surgeons were arranged. For
examinees with probable malignancies, immediate stan-
dard-dose CT and referrals to thoracic surgeons were
arranged. The decision as to how to perform investiga-
tive procedures was left to the referred surgeon. All
cytological and histological findings from biopsies and
surgical specimens were documented. When a cancer
was diagnosed, the examinee received standard care,
including tumor staging and appropriate treatment.
Outcomes of referrals were followed, and cancer-related
details were logged.
Wu et al. BMC Cancer 2011, 11:242
http://www.biomedcentral.com/1471-2407/11/242
Page 2 of 8
Statistical analysis
Statistical analysis was performed using Microsoft Excel
2003 (Microsoft Corporation, Redmond, WA, USA).
The results are presented as mean, median, and range.
The Yates-corrected chi-Square test was used for cate-
gorical variables to evaluate difference. Results were
considered statistically significant at p < 0.05.
Results
From October 2000 to December 2007, a total of 14,040
lung MRI examinations were performed in 11,766 con-
secutive individuals, who were asymptomatic and had
no prior cancer history in the lung or elsewhere. The
mean age was 50.4 years (range, 11-94 years), and 56.8%
of examinees were male. Never-smokers accounted for
89.2% and smokers for 10.8%. The median number of
pack-years of smoking was 22.5 (range, 2-90). No
patients had a history of asbestos exposure. Characteris-
tics of the examinees are shown in Table 1. Of the
11,766 examinees, 10,160 (86.3%) underwent lung MRI
once (only the prevalence examination), 1172 (10%)
twice, and 434 (3.7%) three times or more. Of the
14,040 lung MRI studies, 5037 were performed without
the use of a contrast agent and 9003 with a contrast
agent. Table 2 shows the interindividual comparison of
lung MRI examinations. Contrasted MRI disclosed sig-
nificantly more lung nodules, both benign and suspi-
cious, than noncontrasted MRI (p < 0.001).
A total of 559 people (4.8%) were found to have suspi-
cious lung nodules. Of the 559, 376 (67.3%) had nodules
considered to be benign during follow-up and 138
(24.7%) were lost to follow-up. A total of 49 primary
lung cancers were diagnosed in 46 examinees: 41 preva-
lence cancers and 8 incidence cancers. The rate of pri-
mary lung cancers detected by MRI was 0.4% (49 of
11,766). The detection rate was 0.9% (11 of 1266) for
smokers, and 0.4% (38 of 10,500) for never-smokers
(Table 3). There was no significant difference of cancer
Figure 1 The HASTE images from MRI. The (a) coronal, (b) axial, and (c) sagittal images showed an irregular consolidated mass about 1.2 cm
in diameter at the posterior segment of the right upper lobe. Under black blood preparation, the lesion easily stood out from the clear
background without the appearance of any vessels. (d) The findings from chest radiography were negative. The nodule was surgically proved to
be squamous cell carcinoma, stage Ia.
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detection rate between smokers and never-smokers
(p = 0.11).
Of the 49 lung cancers, the mean age of the individual at
diagnosis was 60.8 years (range, 36-87 years), and 25
(51.0%) were in males. Eleven cases were in people who
had smoked, and the median number of pack-years of
smoking was 35 (range, 10-80). Characteristics of indivi-
duals with detected primary lung cancers are shown in
Table 3. Suspected lung cancers were subjected to various
procedures for proper histopathological documentation.
Thoracotomy (including video-assisted thoracoscopic
surgery) was performed for 40 cancers, lobectomy for 33
cancers, wedge resection for 6, and segmentectomy for 1.
Three cancers were histologically proved by broncho-
scopic biopsy, 1 by CT-guided lung biopsy, 1 by sputum
cytology, 1 by biopsy at supraclavicular lymph node, and 1
by endoscopic biopsy at metastatic duodenal lesion. Two
individuals refused any procedures or therapies and later
developed rib metastases or progressive pulmonary
nodules. Forty cancers had pathological staging, and 9 had
clinical staging. Twenty-five cancers were TNM stage Ia
disease (51.0%), 12 stage Ib disease (24.5%), 4 stage IIIa
Figure 2 Comparison of VIBE images from MRI without and with the use of contrast. The (a) noncontrasted coronal, (b) contrasted
coronal, (c) noncontrasted axial, (d) contrasted axial, (e) noncontrasted sagittal, and (f) contrasted sagittal VIBE images can display clear branches
of pulmonary vessels and bronchial tree with minimal pulsation artifacts in normal lung parenchyma.
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(8.2%), 2 stage IIIb (4.1%), and 6 stage IV disease (12.2%).
The mean size of detected lung cancers was 1.98 cm
(median, 1.5 cm; range, 0.5-8.2 cm). Thirty-six cancers
(73.5%) had a primary tumor measuring ≤3 cm, and 29
(59.2%) ≤2 cm. Histological types were as follows: 38 ade-
nocarcinoma (77.6%), 5 bronchioloalveolar carcinoma
(10.2%), 2 large cell carcinoma (4.1%), 1 squamous cell
carcinoma (2.0%), and 1 carcinoid tumorlet (2.0%). There
were 3 female individuals with synchronous double pri-
mary lung cancers. One biopsy proved to be non-small
cell lung carcinoma with no primary tumor origin in the
lungs when retrospectively and prospectively assessed.
Two cases did not have tissue proof because the indivi-
duals refused any procedures.
Of the 8 incidence cancers, 5 were diagnosed at the
second MRI examination, with a mean interval of 3.3
years (range, 2-5.5 years). Two cancers were diagnosed
at the third annual MRI examination. The comparison
of prevalence cancers and incidence cancers is shown
in Table 4. The mean size of the incidence cancers
was 1.8 cm, compared with 2.0 cm for the prevalence
cancers.
Follow-up (duration, 2-9 years) for the 49 cancers
showed 8 deaths due to lung cancer, 2 stage IIIa cancers,
2 stage IIIb cancers, and 4 stage IV cancers. One stage Ib
individual developed recurrent tumors 2 years later and
underwent pulmonary resection again. Thirty-three indi-
viduals (67.3%) were alive and free of disease at the time
of this writing.
Eight false-positive individuals whose standard-dose
CT also suggested malignancies underwent invasive pro-
cedures: 2 CT-guided biopsies and 6 thoracotomies
(including video-assisted thoracoscopic surgery). Infec-
tious diseases were histologically confirmed in these 8
people, with cryptococcal infections in 6.
Discussion
To date, several studies have investigated the feasibility
of LDCT for screening for primary lung cancers. By
enrolling heavy smokers and older people, these studies
targeted groups at high risk for lung cancer, resulting in
cancer detection rates ranging from 0.4% to 2.7% and
lung nodule prevalence rates ranging from 5.1% to 43%
[13-19]. In our study, there were no limitations on
smoking history and age because all examinations were
self-paid and all examinees were self-enrolled. Conse-
quently, our group included a higher proportion of
never-smokers and a wider age range (11-94 years). If
we calculate the results for smokers between 51 and 70
years old, as did the LDCT studies, the detection rate is
1.4% (6 of 434), and the prevalence of suspicious lung
nodules is 9.0% (39 of 434). The proportion of lung can-
cers among suspicious nodules detected by MRI was
15.4% (6 of 39), higher than in reports for LDCT, which
range from 2.2% to 11.6%. While using standard-dose
CT as a standard-of reference for nodule detection, pre-
vious studies have showed that MRI can achieve high
sensitivity for nodules larger than 1 cm, which are clini-
cal approachable [23,24]. Undoubtedly LDCT is more
sensitive than MRI in detecting lung nodules and
Table 1 Characteristics of individuals undergoing lung
magnetic resonance imaging examination
Age group Never-smoker (female/male) Smoker (female/male)
11-20 34 (14/20) 0 (0/0)
21-30 253 (144/109) 41 (7/34)
31-40 1407 (743/664) 219 (28/191)
41-50 3845 (1807/2038) 538 (41/497)
51-60 2869 (1306/1563) 341 (27/314)
61-70 1394 (689/705) 93 (3/90)
71-80 598 (249/349) 29 (4/25)
81-90 96 (22/74) 5 (0/5)
91-100 4 (1/3) 0 (0/0)
Total 10,500 (4975/5525) 1266 (110/1156)
Table 2 Interindividual comparison of noncontrasted and contrasted lung magnetic resonance imaginga
Result Non contrasted Contrasted Total
Normal or extrapulmonary abnormality 4096 (81.3) 6936 (77.0) 11,032 (78.6)
Lung abnormality of little clinical significance 684 (13.6) 1453 (16.1) 2137 (15.2)
Probable benignancy 88 (1.7) 214 (2.4) 302 (2.2)
Possible malignancy 81 (1.6) 183 (2.0) 264 (1.9)
Probable malignancy 23 (0.5) 56 (0.6) 79 (0.6)
Indeterminate small nodule measuring ≤0.5 cm 65 (1.3) 161 (1.8) 226 (1.6)
Subtotal of suspicious lung nodulesb 169 (3.4) 400 (4.4) 569 (4.1)
Total 5037 (100) 9003 (100) 14,040 (100)
Note: Data are given as number of examinations. Numbers in parentheses are percentages.
aThere was a significant difference between noncontrasted MRI and contrasted MRI by Yates-corrected chi-square test (p < 0.001).
bPossible malignancy, probable malignancy, and indeterminate small nodule are considered to be suspicious lung nodules.
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includes more and smaller nodules. However, for any
diagnostic tool, higher sensitivity is usually accompanied
by lower specificity. Most of the additional lung nodules
detected by LDCT are smaller than 0.5 cm. According
to guidelines for managing small lung nodules, nodules
smaller than 1 cm are associated with more follow-up
visits but not more lung cancers [21,22]. We believe
that it is why our results showed that MRI had a lower
prevalence of suspicious nodules than did LDCT but
had a cancer detection rate similar to that of LDCT.
Contrasted MRI can detect more morphological
details than noncontrasted MRI, and is especially better
at depicting peripheral one-third parenchymal vascular
markings (around 0.2 cm in diameter). The expected
detection limit for contrasted MRI is about 0.3 cm (2 ×
2 pixels), better than noncontrasted MRI about 0.5 cm
(3 × 4 pixels). Nevertheless, our results showed that no
significant difference in cancer detection rates was
found between contrasted and noncontrasted MRI (0.5%
vs 0.4%, p = 0.24). It was assumed that the proportion
of lost to follow-up and false-negative rate of contrasted
MRI were similar to that of noncontrasted MRI because
all examinations and follow-ups were performed in the
same institution. Therefore, the possible explanation
might be the same as previous comparison between
MRI and LDCT. More subtle lung nodules do not
necessarily bring out more lung cancers.
The prevailing argument that MRI is too time-
consuming is no longer a valid concern. In this study,
we demonstrated how a rapid lung MRI study can be
performed with ease. Implementation of the parallel
imaging technique has improved the image quality of
HASTE in the axial and sagittal views. Currently, we
acquire the VIBE sequence in axial, coronal, and sagit-
tal planes by the reduction of TR/TE (2.9 ms/1.1 ms)
and a factor of 2 with integrated parallel acquisition
techniques (iPAT), which is allowed to cover the entire
lung volume within a single breath hold. This optimi-
zation not only permits larger coverage but also
reduces the pulsation artifact from the heart and large
vessels. As shown in Figure 2, VIBE images can display
clear branches of pulmonary vessels and bronchial tree
with minimal pulsation artifacts. Although the resolu-
tion of contrasted MRI is still lower than that of stan-
dard-dose CT, MRI can show most nodules around 0.3
cm as standard-dose CT (Figure 3). The entire MRI
examination of the lungs can be completed in less
than 10 minutes, even if additional scanning is per-
formed for suspicious nodules.
The radiation exposure should be justified when
recommending the use of LDCT as a screening tool.
Several authors have addressed the radiation hazards of
multiple LDCT examinations [25-27]. When lung cancer
screening involves the general population and is not tar-
geted just at the high-risk population, the use of MRI
can avoid the ethical problems of unnecessary ionizing
radiation, which in the long term may contribute to
lung cancer risk [28,29]. In addition, when contrast
study is necessary, gadodiamide is noniodinated and has
a better safety record with less nephrotoxicity [30].
Table 4 Comparison between prevalence lung cancers
and incidence lung cancers by magnetic resonance
imaging examination
Prevalence cancer Incidence cancer
Mean size (cm) 2.0 1.8








Table 3 Distribution of detected primary lung cancers by
magnetic resonance imaging
Never-smoker Smoker
Age group Female Male Female Male Total
31-40 1 (0.1) 0 (0) 0 (0) 1 (0.5) 2 (0.1)
41-50 4 (0.2) 2 (0.1) 1 (2.4) 1 (0.2) 8 (0.2)
51-60 3 (0.2) 7 (0.4) 0 (0) 5 (1.6) 15 (0.5)
61-70 10 (1.5) 3 (0.4) 0 (0) 1 (1.1) 14 (0.9)
71-80 4 (1.6) 2 (0.6) 0 (0) 2 (8.0) 8 (1.3)
81-90 1 (4.5) 1 (1.4) 0 NAb 0 (0) 2 (2.0)
Totala 23 (0.5) 15 (0.3) 1 (0.9) 10 (0.9) 49 (0.4)
Note: Data are given as number of lung cancers. Numbers in parentheses are
percentages.
aThere was no significant difference of cancer detection rate between
smokers and never-smokers by Yates-corrected chi-square test (p = 0.11).
bNot applicable.
Figure 3 Comparison of VIBE images from MRI and standard-
dose CT image. The (a) axial VIBE image and (b) standard-dose CT
image showed a 0.3-cm subpleural nodule.
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In our results, there was no significance of cancer
detection rate between smokers and never-smokers.
However, most studies of lung cancer screening are
aimed at smokers only. Many studies have demonstrated
that lung cancer in never-smokers is an important pub-
lic health issue, especially in females who tend to have
more non-smoking associated cancers than males
[31,32]. Clearly, to perform lung cancer screening in
general population deserves more consideration and
further researches.
Although the results of this study provide helpful insight
into the use of MRI, the study has several limitations. A
certain number of examinees were lost to follow-up.
Moreover, follow-up periods and follow-up tools were not
identical in all individuals. Standard-dose CT and plain
chest radiography were performed only for those with sus-
pected lung lesions; therefore, comparison of MRI with
standard-dose CT and chest radiography for all nodules
was not possible. Without a reference study, the percen-
tage of false-negative cases could not be evaluated. In
addition, like other one-arm observational nonrandomized
trials, our study does not provide information on potential
stage shift and reduction of lung cancer mortality by
screening. Today, several randomized controlled trials of
LDCT are under way worldwide [33-35]. We hope that
our results will prompt subsequent randomized controlled
trials of MRI that are not affected by lead time and length
time bias and overdiagnosis.
Conclusion
Based on the results of more than 10,000 MRI examina-
tions, the 1.5T MRI with advanced pulse sequences
approach described here, which takes less than 10 min-
utes to perform, is useful in lung cancer detection for
asymptomatic individuals and avoids unnecessary ioniz-
ing radiation.
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